Novanta Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY Revenue (est.)
$1.1Bnext fiscal year
FY EPS (est.)
$3.69next fiscal year
Monitoring Framework
Key Performance Indicators
Standalone GAAP Revenue Quarterly257.7MTarget: $1,040 million to $1,055 million for FY 2026
Standalone Adjusted Diluted EPS Quarterly0.8Target: $3.50 to $3.65 for FY 2026
Standalone Adjusted EBITDA Quarterly57MTarget: $245 million to $250 million for FY 2026
Bookings Growth (Year-over-Year) Quarterly3,700.0%Target: Double-digit growth across all business segments
Pro Forma Net Leverage Ratio QuarterlyTarget: Below 2.3x by year-end 2027 (from ~2.7x at close)
Watch Items
- Integration of Riverpoint Medical and realization of synergiesTrigger: Closing of transaction in Q3 2026 and achievement of $6-8 million cost synergies in 2027Action: Monitor Medical Solutions segment margins and progress toward the $80 million cumulative 5-year synergy target.
- De-leveraging trajectory post-acquisitionTrigger: Net leverage ratio exceeding 3.0x gross or failing to drop below 2.3x by year-end 2027Action: Assess free cash flow allocation and potential restrictions on further bolt-on M&A.
- Macroeconomic headwinds and tariff exposuresTrigger: Gross margin compression due to supply chain or trade policy shiftsAction: Evaluate regional manufacturing consolidation execution and pricing power adjustments.
Research as of 19 Jun 2026